News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cell>Point Announces Encouraging Results From 99mTc-EC-G Phase 2a Trial in Evaluating Presence and Severity of Coronary Artery Disease



4/10/2013 12:09:29 PM

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today encouraging results following the conclusion of its Phase 2a cardiovascular clinical study performed by Cardiovascular Imaging Technologies of Kansas City, Missouri. The study imaged patients with technetium-99m-labeled EthylenediCysteine-Glucosamine (99mTc-EC-G), Cell>Point’s proprietary nuclear imaging product candidate, which is target specific for detecting the presence and extent of ischemia in patients with Coronary Artery Disease (CAD).

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES